两种剂量恩度联合顺铂灌注治疗非小细胞肺癌恶性胸腔积液疗效对比

Efficacy Comparison of Two Doses of Endostar Combined with Cisplatin in the Treatment of Non-small Cell Lung Cancer with Malignant Pleural Effusions

探讨两种不同剂量恩度联合顺铂腔内灌注治疗非小细胞肺癌(NSCLC)恶性胸腔积液(MPE)患者疗效及不良反应的差异。将42例NSCLC合并MPE患者分为低剂量组(A组)20例、高剂量组(B组)22例,A组每周予顺铂35mg/m^2/d1+恩度30mg/d2,B组每周予顺铂35mg/m^2/d1+恩度30mg/d2、d4,均连续行胸腔内灌注治疗2周,比较两组疗效、生活质量及不良反应。B组缓解率及疾病控制率为72.73%及95.45%,均显著优于A组的40.00%及70.00%(P<0.05)。两组患者治疗后KPS、QLICP-LU总分、心理功能、咳喘、胸闷痛等领域评分均较治疗前显著增加(P<0.05),B组基本生理功能亦得以改善(P<0.05)。除认知功能外,两组治疗后KPS及QLICP-LU评分差异无统计学意义(P>0.05)。B组药物毒副反应较A组稍大,差异无统计学意义(P>0.05)。高剂量组近期疗效显著优于低剂量组。两种方案均使生活质量获益,高剂量组在基本生理功能及认知方面较低剂量组有一定改善趋势。高剂量组毒副反应较低剂量组稍大,但均可耐受。

This paper used two doses of Endostar combined with cisplatin on non-small cell lung cancer （NSCLC） patients with malignant pleural effusions （MPE）, to explore the difference between their efficacy and adverse reactions. 42 cases of NSCLC patients with MPE were divided into low-dose group （group A, 20 cases） and high-dose group （group B, 22 cases）, group A was given cisplatin 35mg/m2/dl and Endostar 30rag/d2 per week, group B was given cisplatin 35rag/m2/ dl and Endostar 30mg/d2, d4 per week, consecutively treated by intrapleural instillation for 2 weeks. The authors compared the differences between their treatment effect, quality of life and adverse reaction. The response rate and disease control rate of group B were 72.73% and 95.45%, which were significantly higher than that of group A （40%and 70%） （P〈0. 05）. After treatment, KPS and QLICP-LU score of the two groups were significantly improved （P〈0.05）, fields of psychological function, cough, chest pain, fear of others had improvement （P〈0. 05）, and basic physiological functions of group B have already been improved （P〈0.05）. KPS and QLICP-LU score of the two groups after treatment did not reflect significant differences （P〈0.05） except cognitive score. The adverse reactions of group B were slightly larger than group A, the difference had no significant statistical difference （P〈0.05）. The short-term therapeutic effect of high-dose group is significantly better than low-dose group. Both of the two dosages made life quality of NSCLC patients with MPE to get benefit, the basic physiological function and cognitive aspects of the high-dose group has certain improvement trend. Adverse drug reaction of the high-dose group is slightly larger, both of the two groups could be tolerated.